Classical phenylketonuria (PKU) is a rare metabolic disorder, resulting from a deficiency of a liver enzyme, phenylalanine hydroxylase. The deficiency of the enzyme leads to elevated phenylalanine (Phe) levels in the blood and various tissues including the brain. The incidence in Caucasians is approximately one in 10,000, giving a heterozygote frequency of one in 50 to one in 70. About one in 15,000 infants is born with PKU in the United States.
KeywordsToxicity Osteoporosis Tyrosine Cysteine Arginine
- Feillet, F., & Agostoni, C. (2010). Nutritional issues in treating phenylketonuria. Journal of Inherited Metabolic Disease, 33, 659–664.Google Scholar
- Hoeks, M. P. A., den Heijer, M., & Janssen, M. C. H. (2009). Adult issues in phenylketonuria. Netherlands Journal of Medicine, 67, 1–7.Google Scholar
- Koch, R. K. (1999). Issues in newborn screening for phenylketonuria. American Family Physician, 605, 1462–1466.Google Scholar
- Mitchell, J. J. (2013). Phenylalanine hydroxylase deficiency. GeneReviews. Updated 31 Jan 2013. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1504/
- Scriver, C. R., & Kaufman, S. (2001). Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency, Chapter 77. In C. R. Scriver, A. L. Beaudet, W. S. Sly, & D. Valle (Eds.), The metabolic & molecular bases of inherited disease (8th ed., pp. 1667–1724). New York: McGraw-Hill.Google Scholar
- Vajro, P., Striscìuglio, P., Houssin, D., et al. (1993). Correction of phenylketonuria after liver transplantation in a child with cirrhosis. New England Journal of Medicine, 29, 329–363.Google Scholar